SRR10842369
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.500
- MYC_TARGETS_V2+0.500
- ALLOGRAFT_REJECTION+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.300
- PROTEIN_SECRETION+0.300
- APOPTOSIS+0.200
- IL2_STAT5_SIGNALING+0.200
- NOTCH_SIGNALING+0.200
Top 10 suppressed
- ANGIOGENESIS-0.300
- E2F_TARGETS-0.300
- PANCREAS_BETA_CELLS-0.300
- ESTROGEN_RESPONSE_LATE-0.200
- KRAS_SIGNALING_DN-0.200
- MYOGENESIS-0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.200
- SPERMATOGENESIS-0.200
- WNT_BETA_CATENIN_SIGNALING-0.200
- APICAL_SURFACE-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934833 | — | — | 0.753 |
| 2 | SRR934940 | — | — | 0.750 |
| 3 | 131534 | EPN | EPN Tumor | 0.747 |
| 4 | MNG765 | — | — | 0.732 |
| 5 | SRR934745 | — | — | 0.715 |
| 6 | C1CCE12B-8892-49AB-8DF2-E5E280DEAE32 | — | — | 0.713 |
| 7 | SJEPD030229_D1.RNA-Seq | EPN | Supratentorial EPN | 0.713 |
| 8 | SRR23303760 | — | — | 0.713 |
| 9 | SRR934943 | — | — | 0.712 |
| 10 | MNG596 | — | — | 0.710 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |